Susceptibility genes in movement disorders

Movement Disorders

Volumn 23, Issue 7, 2008, Pages 927-934

  Scholz, Sonja ^a,b   Singleton, Andrew ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Candidate gene; Link age study; Movement disorder; Susceptibility gene; Whole genome association study

Indexed keywords

ADENOSINE TRIPHOSPHATE 13A2; ALPHA SYNUCLEIN; ATAXIN 1; ATAXIN 10; ATAXIN 2; ATAXIN 3; ATAXIN 7; ATM PROTEIN; DJ 1 PROTEIN; FIBROBLAST GROWTH FACTOR 14; FRAGILE X MENTAL RETARDATION PROTEIN; GENE PRODUCT; LEUCINE RICH REPEAT KINASE 2; PARKIN; PROTEIN IT15; PROTEIN ITPR1; PROTEIN JPH3; PROTEIN KCNC3; PROTEIN KLHL1; PROTEIN MAPT; PROTEIN NR4A2; PROTEIN PINK1; PROTEIN PPP2R2B; PROTEIN PRKCG; PROTEIN PRNP; PROTEIN SPTBN2; PROTEIN TAF1; SERINE PROTEINASE OMI; TORSIN A; UNCLASSIFIED DRUG; CHAPERONE; TOR1A PROTEIN, HUMAN;

DISEASE PREDISPOSITION; GENE DELETION; GENE DUPLICATION; GENE INSERTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LINKAGE ANALYSIS; MOLECULAR CLONING; MOTOR DYSFUNCTION; PATHOPHYSIOLOGY; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRINUCLEOTIDE REPEAT; ALLELE; CHROMOSOME ABERRATION; GENETIC PREDISPOSITION; GENETICS; GENOMICS; GENOTYPE; METHODOLOGY;

ALLELES; CHROMOSOME ABERRATIONS; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; GENOTYPE; HUMANS; LINKAGE (GENETICS); MOLECULAR CHAPERONES; MOVEMENT DISORDERS; PHENOTYPE; POINT MUTATION;

EID: 49249134407     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21983     Document Type: Review

References (19)

1. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
2. Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet 2001;10:3101-3109.
3. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003;302:841.
4. Miller DW, Hague SM, Clarimon J, et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004;62:1835-1838.
5. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-259.
6. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.
7. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600.
8. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;304:1159-1160.
9. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607.
10. Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005;365:410-412.
11. Carmine Belin A, Westerlund M, Sydow O, et al. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Mov Disord 2006;21:1731-1734.
12. Kay DM, Kramer P, Higgins D, Zabetian CP, Payami H. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov Disord 2005;20:1077-1078.
13. Funayama M, Li Y, Tomiyama H, et al. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 2007;18:273-275.
14. Abou-Sleiman PM, Muqit MM, McDonald NQ, et al. A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol 2006;60:414-419.
15. Bonifati V, Rohe CF, Breedveld GJ, et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005;65:87-95.
16. Djarmati A, Hedrich K, Svetel M, et al. Heterozygous PINK1 mutations: a susceptibility factor for Parkinson disease? Mov Disord 2006;21:1526-1530.
17. Hedrich K, Hagenah J, Djarmati A, et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Arch Neurol 2006;63:833-838.
18. Khan NL, Valente EM, Bentivoglio AR, et al. Clinical and sub-clinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 2002;52:849-853.
19. Lincoln SJ, Maraganore DM, Lesnick TG, et al. Parkin variants in North American Parkinson's disease: cases and controls. Mov Disord 2003;18:1306-1311.